CYTK

Cytokinetics, Incorporated NASDAQ

Healthcare ·Biotechnology ·US · cytokinetics.com

$66.05

Mkt Cap $8.1B

52w Low $29.31 88.2% of range 52w High $70.98

50d MA $63.75 200d MA $57.63

P/E (TTM) -9.7x

EV/EBITDA -10.4x

P/B —

Debt/Equity -1.9x

ROE 119.0%

P/FCF -14.3x

RSI (14) —

ATR (14) —

Beta 0.48

50d MA $63.75

200d MA $57.63

Avg Volume 1.9M

About

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin act…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 24, 2026	AMC	-1.48	-1.50	-1.4%	70.10	-2.8%	-10.3%	-10.7%	-11.2%	-12.4%	-13.4%	-9.4%	—
Nov 5, 2025	AMC	-1.59	-1.54	+3.1%	59.19	-0.6%	+1.9%	+1.6%	+5.1%	+12.4%	+11.4%	+10.9%	—
Aug 7, 2025	AMC	-1.34	-1.12	+16.4%	35.25	+1.7%	-3.2%	-5.7%	-2.7%	+4.6%	+9.8%	+47.8%	—
May 6, 2025	AMC	-1.41	-1.36	+3.5%	33.97	+4.0%	-2.7%	-4.4%	-6.7%	-5.4%	-9.9%	-5.6%	—
Feb 27, 2025	AMC	-1.29	-1.26	+2.3%	47.45	-6.5%	-3.1%	-9.6%	-7.9%	-7.5%	-8.8%	-15.3%	—
Nov 6, 2024	AMC	-1.27	-1.36	-7.1%	55.50	-0.9%	+0.6%	+4.5%	+5.6%	+1.2%	+0.8%	-8.2%	—
Aug 8, 2024	AMC	-1.02	-1.31	-28.4%	54.00	-3.7%	+3.3%	+4.0%	+3.8%	+3.5%	+5.7%	+3.4%	—
May 8, 2024	AMC	-1.16	-1.33	-14.7%	65.27	+4.5%	-1.9%	-4.9%	-11.3%	-9.1%	-7.3%	-19.1%	—
Feb 27, 2024	AMC	-1.03	-1.38	-34.0%	80.99	-3.8%	-9.8%	-10.8%	-8.7%	-16.4%	-18.0%	-13.4%	—
Nov 2, 2023	AMC	-0.72	-1.35	-87.5%	34.64	+2.3%	+4.8%	-0.6%	+3.5%	+0.3%	-4.4%	-2.2%	—
Aug 3, 2023	AMC	-1.23	-1.34	-8.9%	31.70	+0.9%	+4.7%	-1.1%	+0.8%	+0.3%	+2.5%	+10.9%	—
May 4, 2023	AMC	-1.24	-1.38	-11.3%	39.29	+4.3%	+0.4%	-2.2%	-1.1%	-0.2%	-3.7%	-3.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 6	Barclays	Maintains	Overweight → Overweight	—	$66.73	$66.09	-1.0%	-2.7%	-1.9%	-1.4%	-3.2%	-2.6%
Mar 18	Mizuho	Maintains	Outperform → Outperform	—	$62.13	$61.50	-1.0%	+0.1%	+1.3%	-0.7%	-1.9%	-3.4%
Mar 17	JP Morgan	Maintains	Overweight → Overweight	—	$60.83	$60.94	+0.2%	+2.1%	+2.2%	+3.5%	+1.4%	+0.2%
Mar 6	UBS	Maintains	Neutral → Neutral	—	$62.19	$61.38	-1.3%	-2.9%	+0.4%	+3.2%	+2.3%	-3.5%
Feb 26	Leerink Partners	Maintains	Outperform → Outperform	—	$62.89	$62.61	-0.4%	-0.4%	-1.1%	-2.3%	-3.5%	-1.0%
Feb 25	Citizens	Maintains	Market Outperform → Market Outperform	—	$70.10	$68.12	-2.8%	-10.3%	-10.7%	-11.2%	-12.4%	-13.4%
Feb 25	Needham	Maintains	Buy → Buy	—	$70.10	$68.12	-2.8%	-10.3%	-10.7%	-11.2%	-12.4%	-13.4%
Feb 20	RBC Capital	Maintains	Outperform → Outperform	—	$67.83	$67.72	-0.2%	+0.2%	+0.6%	+3.3%	-7.3%	-7.7%
Feb 3	Truist	Maintains	Buy → Buy	—	$65.16	$65.86	+1.1%	-0.7%	-2.5%	-7.6%	-4.3%	-2.8%
Jan 21	B. Riley Securities	Maintains	Buy → Buy	—	$63.78	$64.69	+1.4%	-1.2%	+1.8%	-0.6%	-0.9%	+0.4%
Jan 21	RBC Capital	Maintains	Outperform → Outperform	—	$63.78	$64.69	+1.4%	-1.2%	+1.8%	-0.6%	-0.9%	+0.4%
Jan 20	JP Morgan	Maintains	Overweight → Overweight	—	$62.58	$61.89	-1.1%	+1.9%	+0.7%	+3.8%	+1.3%	+1.0%
Dec 23	Morgan Stanley	Maintains	Overweight → Overweight	—	$65.60	$64.97	-1.0%	-3.5%	-2.2%	-3.8%	-5.9%	-6.4%
Dec 22	Barclays	Maintains	Overweight → Overweight	—	$62.72	$64.00	+2.0%	+4.6%	+0.9%	+2.3%	+0.6%	-1.5%
Dec 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$62.72	$64.00	+2.0%	+4.6%	+0.9%	+2.3%	+0.6%	-1.5%
Dec 22	RBC Capital	Maintains	Outperform → Outperform	—	$62.72	$64.00	+2.0%	+4.6%	+0.9%	+2.3%	+0.6%	-1.5%
Dec 22	Citizens	Maintains	Market Outperform → Market Outperform	—	$62.72	$64.00	+2.0%	+4.6%	+0.9%	+2.3%	+0.6%	-1.5%
Dec 22	Needham	Maintains	Buy → Buy	—	$62.72	$64.00	+2.0%	+4.6%	+0.9%	+2.3%	+0.6%	-1.5%
Dec 19	Goldman Sachs	Upgrade	Neutral → Buy	—	$62.20	$62.93	+1.2%	+0.8%	+5.5%	+1.8%	+3.2%	+1.5%
Dec 12	Needham	Maintains	Buy → Buy	—	$60.77	$60.99	+0.4%	+4.2%	+2.3%	+2.1%	-1.6%	+2.4%
Nov 11	RBC Capital	Maintains	Outperform → Outperform	—	$62.20	$62.16	-0.1%	+6.9%	+6.0%	+5.3%	+6.8%	+7.6%
Nov 10	B. Riley Securities	Maintains	Buy → Buy	—	$60.16	$60.30	+0.2%	+3.4%	+10.5%	+9.6%	+8.9%	+10.4%
Oct 6	Barclays	Maintains	Overweight → Overweight	—	$56.97	$57.87	+1.6%	+6.4%	+5.6%	+6.8%	+5.9%	+5.4%
Oct 2	BofA Securities	Maintains	Neutral → Neutral	—	$55.84	$56.16	+0.6%	+0.9%	+2.0%	+8.6%	+7.8%	+8.9%
Sep 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$50.40	$50.19	-0.4%	+6.9%	+9.0%	+10.8%	+11.7%	+13.0%
Sep 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$48.66	$48.99	+0.7%	-0.8%	-0.2%	-0.8%	-1.7%	+3.6%
Sep 22	B. Riley Securities	Maintains	Buy → Buy	—	$48.66	$48.99	+0.7%	-0.8%	-0.2%	-0.8%	-1.7%	+3.6%
Sep 3	Barclays	Maintains	Overweight → Overweight	—	$49.62	$49.90	+0.6%	+0.7%	+0.3%	+6.8%	+5.0%	+3.8%
Sep 3	Evercore ISI	Maintains	Outperform → Outperform	—	$49.62	$49.90	+0.6%	+0.7%	+0.3%	+6.8%	+5.0%	+3.8%
Sep 2	Stifel	Maintains	Buy → Buy	—	$35.33	$44.91	+27.1%	+40.4%	+41.5%	+40.8%	+50.0%	+47.4%
Sep 2	Needham	Maintains	Buy → Buy	—	$35.33	$44.91	+27.1%	+40.4%	+41.5%	+40.8%	+50.0%	+47.4%
Sep 2	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$35.33	$44.91	+27.1%	+40.4%	+41.5%	+40.8%	+50.0%	+47.4%
Sep 2	Citigroup	Maintains	Buy → Buy	—	$35.33	$44.91	+27.1%	+40.4%	+41.5%	+40.8%	+50.0%	+47.4%
Aug 8	Citigroup	Maintains	Buy → Buy	—	$35.25	$35.85	+1.7%	-3.2%	-5.7%	-2.7%	+4.6%	+9.8%
Jun 9	JP Morgan	Maintains	Overweight → Overweight	—	$32.30	$32.95	+2.0%	+2.6%	+6.9%	+2.5%	+2.8%	+6.4%
May 29	Mizuho	Maintains	Outperform → Outperform	—	$30.28	$30.23	-0.2%	+3.4%	+2.4%	+3.1%	+5.7%	+7.0%
May 14	Needham	Maintains	Buy → Buy	—	$30.61	$30.50	-0.4%	-2.0%	-2.5%	+1.3%	+0.5%	+6.7%
May 8	Barclays	Maintains	Overweight → Overweight	—	$33.04	$32.76	-0.8%	-1.7%	-4.1%	-2.8%	-7.4%	-9.2%
May 7	RBC Capital	Maintains	Outperform → Outperform	—	$33.97	$35.34	+4.0%	-2.7%	-4.4%	-6.7%	-5.4%	-9.9%
May 7	Citigroup	Maintains	Buy → Buy	—	$33.97	$35.34	+4.0%	-2.7%	-4.4%	-6.7%	-5.4%	-9.9%
May 2	Needham	Maintains	Buy → Buy	—	$42.92	$37.67	-12.2%	-13.0%	-14.6%	-20.9%	-23.0%	-24.3%
May 2	UBS	Maintains	Neutral → Neutral	—	$42.92	$37.67	-12.2%	-13.0%	-14.6%	-20.9%	-23.0%	-24.3%
Apr 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$39.48	$38.90	-1.5%	-3.9%	-4.2%	-3.7%	+2.2%	+2.4%
Apr 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$39.81	$38.91	-2.3%	-3.1%	-1.7%	-0.8%	-4.7%	-5.0%
Apr 15	BofA Securities	Maintains	Neutral → Neutral	—	$39.81	$38.91	-2.3%	-3.1%	-1.7%	-0.8%	-4.7%	-5.0%
Apr 10	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$37.32	$36.20	-3.0%	+1.4%	+3.6%	+6.7%	+3.3%	+4.9%
Apr 8	Needham	Maintains	Buy → Buy	—	$35.99	$36.52	+1.5%	-3.9%	+3.7%	+5.2%	+7.4%	+10.6%
Apr 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.52	$40.44	-0.2%	-7.8%	-11.2%	-14.7%	-7.9%	-6.6%
Apr 3	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$40.25	$39.43	-2.0%	+0.7%	-7.2%	-10.6%	-14.1%	-7.3%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$47.45	$44.36	-6.5%	-3.1%	-9.6%	-7.9%	-7.5%	-8.8%

Recent Filings

8-K

Cytokinetics Inc. -- 8-K Filing

Cytokinetics' MYQORZO received regulatory approvals across the U.S., China, and Europe for symptomatic obstructive hypertrophic cardiomyopathy, with U.S. commercialization launching immediately and multiple pipeline catalysts expected through 2026.

Feb 24

8-K · 8.01 !! High

Cytokinetics Inc. -- 8-K 8.01: Material Event / Announcement

Cytokinetics received European Commission approval for MYQORZO (aficamten) to treat obstructive hypertrophic cardiomyopathy, expanding the company's commercial opportunities in a major market.

Feb 17

Data updated apr 25, 2026 4:28am · Source: massive.com